Petros Pharmaceuticals Inc (PTPI) USD0.0001

Sell:$0.05Buy:$0.05$0.00 (5.47%)

Prices delayed by at least 15 minutes
Sell:$0.05
Buy:$0.05
Change:$0.00 (5.47%)
Prices delayed by at least 15 minutes
Sell:$0.05
Buy:$0.05
Change:$0.00 (5.47%)
Prices delayed by at least 15 minutes

Company Information

About this company

Petros Pharmaceuticals, Inc. is focused on the self-care market by providing expanded access to key prescription pharmaceuticals such as OTC treatment options. The Company is engaged in developing a software-as-a-service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch. In addition to the SaaS component, the platform is intended to incorporate software as a medical device (SaMD) capabilities, transforming traditional OTC medications into digitally enabled solutions. The SaMD interface seeks to be designed as customized and branded to pharmaceutical therapy and established as a specific application pathway to that therapy. Together, it aims to develop the SaaS and SaMD components to create a scalable, licensable platform that supports various classes of medications across the pharmaceutical industry, assisting pharmaceutical companies achieve regulatory approval, while delivering consumer-focused healthcare solutions.

Key people

Fady Boctor
President, Chief Commercial Officer
Mitchell Arnold
Chief Accounting Officer, Vice President - Finance
Joshua N. Silverman
Independent Non-Executive Chairman of the Board
Bruce T. Bernstein
Independent Director
Wayne R. Walker
Independent Director
Click to see more

Key facts

  • EPIC
    PTPI
  • Location
    United States
  • Sector
    Technology
  • Industry
    Software & Programming
  • ISIN
    US71678J2096
  • Market cap
    $2.65m
  • Employees
    18
  • Shares in issue
    53.52m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.